BACKGROUND: The Obesity Surgery Mortality Risk Score (OS-MRS) has been proposed as a user-friendly tool for the assessment and risk stratification of patients undergoing Roux-en-Y gastric bypass (RYGB). We assessed the validity of the OS-MRS in 2121 primary RYGB procedures performed at our center during a 25-year period. METHODS: A retrospective study of the patients who had undergone primary RYGB since 1983 was performed. The 90-day mortality and all mortalities related to complications of the RYGB were determined. For every patient, we assigned the relevant risk score according to their co-morbidities and relevant demographics. Each patient was assigned to a class (A, B, or C) according to the OS-MRS. We used the Z test to estimate whether the difference between the actual and predicted risk using the OS-MRS was statistically significant. RESULTS: We identified 2121 patients who had undergone primary RYGB, of which 1254 (59%) were open (ORYGB) and 867 (41%) were laparoscopic (LRYGB). The mean body mass index was 50.7 +/- 8.6 kg/m(2), and the mean age was 39.7 +/- 9.9 years. The mortality rate for ORYGB was 1% (13 patients) and for LRYGB was .4% (4 patients). The overall mortality rate was .8% (17 patients). Of the 2121 patients, 1385 (65%) were in class A, 671 (32%) were in class B, and 65 (3%) were in class C. The expected versus observed mortality rate was .3% versus .3% for class A, 1.9% versus 1.5% for class B, and 7.5% versus 3% for class C, respectively. The difference between the mortality expected from applying the OS-MRS in our cohort and the observed mortality was assessed for statistical significance using Flora's Z statistic. No significant difference was found between the observed and expected mortality, suggesting that the OS-MRS was a valid tool for predicting mortality in our cohort. CONCLUSION: In our bariatric center with >25 years' experience, the OS-MRS accurately predicted the postoperative mortality for RYGB surgery. It appears to be a user-friendly scoring system that could facilitate the informed consent process. Before the system is unequivocally adopted, additional validation trials of a prospective nature are required.
BACKGROUND: The Obesity Surgery Mortality Risk Score (OS-MRS) has been proposed as a user-friendly tool for the assessment and risk stratification of patients undergoing Roux-en-Y gastric bypass (RYGB). We assessed the validity of the OS-MRS in 2121 primary RYGB procedures performed at our center during a 25-year period. METHODS: A retrospective study of the patients who had undergone primary RYGB since 1983 was performed. The 90-day mortality and all mortalities related to complications of the RYGB were determined. For every patient, we assigned the relevant risk score according to their co-morbidities and relevant demographics. Each patient was assigned to a class (A, B, or C) according to the OS-MRS. We used the Z test to estimate whether the difference between the actual and predicted risk using the OS-MRS was statistically significant. RESULTS: We identified 2121 patients who had undergone primary RYGB, of which 1254 (59%) were open (ORYGB) and 867 (41%) were laparoscopic (LRYGB). The mean body mass index was 50.7 +/- 8.6 kg/m(2), and the mean age was 39.7 +/- 9.9 years. The mortality rate for ORYGB was 1% (13 patients) and for LRYGB was .4% (4 patients). The overall mortality rate was .8% (17 patients). Of the 2121 patients, 1385 (65%) were in class A, 671 (32%) were in class B, and 65 (3%) were in class C. The expected versus observed mortality rate was .3% versus .3% for class A, 1.9% versus 1.5% for class B, and 7.5% versus 3% for class C, respectively. The difference between the mortality expected from applying the OS-MRS in our cohort and the observed mortality was assessed for statistical significance using Flora's Z statistic. No significant difference was found between the observed and expected mortality, suggesting that the OS-MRS was a valid tool for predicting mortality in our cohort. CONCLUSION: In our bariatric center with >25 years' experience, the OS-MRS accurately predicted the postoperative mortality for RYGB surgery. It appears to be a user-friendly scoring system that could facilitate the informed consent process. Before the system is unequivocally adopted, additional validation trials of a prospective nature are required.
Authors: Maria Luisa García-García; Juan Gervasio Martín-Lorenzo; Ramón Lirón-Ruiz; José Antonio Torralba-Martínez; José Antonio García-López; José Luis Aguayo-Albasini Journal: Obes Surg Date: 2017-06 Impact factor: 4.129
Authors: Mark D Smith; Emma Patterson; Abdus S Wahed; Steven H Belle; Paul D Berk; Anita P Courcoulas; Gregory F Dakin; David R Flum; Laura Machado; James E Mitchell; John Pender; Alfons Pomp; Walter Pories; Ramesh Ramanathan; Beth Schrope; Myrlene Staten; Akuezunkpa Ude; Bruce M Wolfe Journal: Obes Surg Date: 2011-11 Impact factor: 4.129
Authors: Hugo Meunier; Benjamin Menahem; Yannick Le Roux; Adrien Lee Bion; Yoann Marion; Antoine Vallois; Nicolas Contival; Thomas Gautier; Jean Lubrano; Anaïs Briant; Jean-Jacques Parienti; Arnaud Alves Journal: Obes Surg Date: 2021-04-28 Impact factor: 4.129
Authors: Piotr Major; Michał Wysocki; Michał Pędziwiatr; Piotr Małczak; Magdalena Pisarska; Marcin Migaczewski; Marek Winiarski; Andrzej Budzyński Journal: Wideochir Inne Tech Maloinwazyjne Date: 2016-12-06 Impact factor: 1.195
Authors: Usha K Coblijn; Julian Karres; Christel A L de Raaff; Steve M M de Castro; Sjoerd M Lagarde; Willem F van Tets; H Jaap Bonjer; Bart A van Wagensveld Journal: Surg Endosc Date: 2017-03-31 Impact factor: 4.584
Authors: Mikołaj Orłowski; Michał R Janik; Krzysztof Paśnik; Emil Jędrzejewski Journal: Wideochir Inne Tech Maloinwazyjne Date: 2015-06-19 Impact factor: 1.195